Truist Securities bolsters healthcare investment banking team
Truist Securities has announced three key appointments to its healthcare investment banking team, enhancing its industry expertise. Jefferson Rives, with 20 years of experience, joins as managing director and head of healthcare technology from Barclays. Max Riso, with 11 years in healthcare investment banking, becomes managing director in biotech, coming from Citi. Dheeraj Chinthalapelly, with over eight years of experience, joins as director in biotech from UBS and Credit Suisse.
These strategic hires aim to capitalize on the robust activity in Truist's healthcare practice and anticipated industry momentum. The expanded team is expected to deliver innovative solutions and actionable ideas to clients navigating the evolving healthcare landscape.
Truist Securities ha annunciato tre importanti nomine per il suo team di investment banking nel settore sanitario, migliorando la propria expertise nel settore. Jefferson Rives, con 20 anni di esperienza, entra come direttore generale e responsabile della tecnologia sanitaria proveniente da Barclays. Max Riso, con 11 anni di esperienza nell'investment banking sanitario, diventa direttore generale nel settore biotech, arrivando da Citi. Dheeraj Chinthalapelly, con oltre otto anni di esperienza, si unisce come direttore nel biotech proveniente da UBS e Credit Suisse.
Queste assunzioni strategiche mirano a sfruttare l'attività robusta nella pratica sanitaria di Truist e il previsto slancio del settore. Il team ampliato dovrebbe fornire soluzioni innovative e idee praticabili ai clienti che navigano nell'evoluzione del panorama sanitario.
Truist Securities ha anunciado tres nombramientos clave para su equipo de banca de inversión en el sector de la salud, mejorando su experiencia en la industria. Jefferson Rives, con 20 años de experiencia, se une como director gerente y jefe de tecnología en salud procedente de Barclays. Max Riso, con 11 años en banca de inversión en salud, se convierte en director gerente en biotecnología, viniendo de Citi. Dheeraj Chinthalapelly, con más de ocho años de experiencia, se une como director en biotecnología desde UBS y Credit Suisse.
Estos nombramientos estratégicos tienen como objetivo capitalizar la sólida actividad en la práctica de salud de Truist y el impulso anticipado en la industria. Se espera que el equipo ampliado ofrezca soluciones innovadoras e ideas prácticas a los clientes que navegan por el panorama sanitario en evolución.
Truist Securities는 의료 투자 은행 팀에 대한 세 가지 주요 임명을 발표하며 산업 전문성을 강화했습니다. Jefferson Rives는 20년의 경력을 지닌 의료 기술 책임자와 전무이사로 Barclays에서 합류했습니다. Max Riso는 의료 투자 은행 분야에서 11년의 경력을 가지고 있어, Citi에서 올 바이오텍의 전무이사가 되었습니다. Dheeraj Chinthalapelly는 8년 이상의 경험을 가진 바이오텍 디렉터로 UBS와 Credit Suisse에서 합류합니다.
이러한 전략적 채용은 Truist의 의료 분야에서의 활발한 활동과 예상되는 산업의 탄력을 활용하려는 목표가 있습니다. 확대된 팀은 변화하는 의료 환경을 탐색하는 고객에게 혁신적인 솔루션과 실행 가능한 아이디어를 제공할 것으로 기대됩니다.
Truist Securities a annoncé trois nominations clés pour son équipe de banque d'investissement dans le secteur de la santé, renforçant ainsi son expertise sectorielle. Jefferson Rives, fort de 20 ans d'expérience, rejoint comme directeur général et responsable de la technologie de la santé en provenance de Barclays. Max Riso, avec 11 ans d'expérience dans le secteur de la banque d'investissement en santé, devient directeur général en biotechnologie, venant de Citi. Dheeraj Chinthalapelly, avec plus de huit ans d'expérience, rejoint en tant que directeur en biotechnologie en provenance de UBS et de Credit Suisse.
Ces recrutements stratégiques visent à tirer parti de l'activité dynamique dans la pratique de la santé de Truist et de l'élan anticipé de l'industrie. L'équipe élargie devrait fournir des solutions innovantes et des idées concrètes aux clients qui naviguent dans le paysage sanitaire en évolution.
Truist Securities hat drei wichtige Ernennungen für sein Team im Bereich Healthcare-Investmentbanking bekannt gegeben, um die Fachkompetenz in der Branche zu verstärken. Jefferson Rives mit 20 Jahren Erfahrung kommt als Geschäftsführer und Leiter für Gesundheitstechnologie von Barclays. Max Riso, der über 11 Jahre Erfahrung im Healthcare-Investmentbanking verfügt, wird Geschäftsführer im Bereich Biotechnologie und wechselt von Citi. Dheeraj Chinthalapelly bringt mehr als acht Jahre Erfahrung mit und tritt als Direktor im Bereich Biotechnologie von UBS und Credit Suisse bei.
Diese strategischen Einstellungen zielen darauf ab, die robuste Tätigkeit in Truists Gesundheitsbereich und den bevorstehenden Branchenaufschwung zu nutzen. Das erweiterte Team wird erwartet, dass es innovative Lösungen und umsetzbare Ideen für Kunden entwickelt, die sich im sich wandelnden Gesundheitsumfeld zurechtfinden müssen.
- Expansion of healthcare investment banking team with three experienced professionals
- Strengthening of expertise in healthcare technology and biotech sectors
- Robust activity reported in Truist's healthcare practice
- None.
New additions expand depth and breadth of platform
- Jefferson Rives, managing director and head of healthcare technology, joins from Barclays. Rives has 20 years of experience, including leading roles within the Wells Fargo and Morgan Stanley global healthcare teams. He is a graduate of the University of
North Carolina –Chapel Hill and received his MBA from the Kellogg School of Management at Northwestern University. - Max Riso, managing director, biotech, joins from Citi's healthcare investment banking group. Riso has 11 years of healthcare investment banking experience, including roles with PJT Partners and Jefferies. He is a graduate of the University of
Florida and received his MBA from the University ofMichigan's Ross School of Business. - Dheeraj Chinthalapelly, director, biotech, joins from UBS and Credit Suisse, where he collectively spent more than eight years. He is a graduate of the India Institute of Technology and received his MBA from NYU Stern School of Business.
"Our healthcare practice has seen robust activity this year and we anticipate momentum in the industry will continue," said Pat Stevens, head of Healthcare Investment Banking Group. "The addition of
Riso and Chinthalapelly will be based in
About Truist Securities
Truist Securities is the full-service corporate and investment banking arm of Truist Financial Corporation (NYSE: TFC). With a rich history extending back more than 125 years, Truist Securities offers a robust capital markets and investment banking platform that includes a comprehensive array of strategic advisory, mergers and acquisition, and capital markets capabilities for corporate and institutional clients, including sales, trading, and research services in both fixed income and equity. The firm also provides corporate finance, asset finance, risk management, liquidity, and treasury management solutions to meet clients' full spectrum of financial needs. Headquartered in
© 2024 Truist Financial Corporation. Truist and Truist Securities are service marks of Truist Financial Corporation. All rights reserved. Truist Securities is the trade name for the corporate and investment banking services of Truist Financial Corporation and its subsidiaries. Securities and strategic advisory services are provided by Truist Securities, Inc., member FINRA and SIPC. Lending, financial risk management, and treasury management and payment services are offered by Truist Bank. Deposit products are offered by Truist Bank, Member FDIC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/truist-securities-bolsters-healthcare-investment-banking-team-302222825.html
SOURCE Truist Financial Corporation
FAQ
Who are the new appointments to Truist Securities' healthcare investment banking team?
What is the professional background of Jefferson Rives, the new head of healthcare technology at Truist Securities?
How does Truist Securities (TFC) expect these new hires to impact their healthcare practice?
Where will the new appointees be based within Truist Securities (TFC)?
